Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about TransMedics Group, Inc.
TransMedics Group, Inc. News
Jan 28, 2025 - globenewswire.com
TransMedics Group, Inc. Announcement: If You Have Suffered Losses in TransMedics Group, Inc. (NASDAQ: TMDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Jan 28, 2025 - globenewswire.com
TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking – Hagens Berman
Jan 28, 2025 - accessnewswire.com
TMDX INVESTIGATION ALERT: TransMedics Group, Inc. is being Investigated for Securities Fraud - Contact BFA Law if You Lost Money on Your Investment
Jan 28, 2025 - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TransMedics Group, Inc. - TMDX
TransMedics Group, Inc. Quantitative Score
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc. Earnings & Revenue
TransMedics Group, Inc. Financials
Table Compare
Compare TMDX metrics with: | |||
|---|---|---|---|
Earnings & Growth | TMDX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | TMDX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | TMDX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | TMDX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
TransMedics Group, Inc. Income
TransMedics Group, Inc. Balance Sheet
TransMedics Group, Inc. Cash Flow
TransMedics Group, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Buy |
| Return on Assets | Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
TransMedics Group, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
TransMedics Group, Inc. Executives
| Name | Role |
|---|---|
| Dr. Waleed H. Hassanein M.D. | Founder, President, Chief Executive Officer & Director |
| Dr. Tamer I. Khayal M.D. | Chief Commercial Officer |
| Mr. Nicholas Corcoran | Senior Vice President of Supply Chain & Operations |
| Mr. Anil Ranganath | Senior Vice President, General Counsel & Corporate Secretary |
| Ms. Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Waleed H. Hassanein M.D. | Founder, President, Chief Executive Officer & Director | 1968 | 1.82M | |
| Dr. Tamer I. Khayal M.D. | Chief Commercial Officer | 1969 | 900.11K | |
| Mr. Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | Male | 1983 | 812.07K |
| Mr. Anil Ranganath | Senior Vice President, General Counsel & Corporate Secretary | Male | 561.67K | |
| Ms. Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs | Female | 1961 | 535.93K |
TransMedics Group, Inc. Insider Trades
| Date | 7 Jan |
| Name | Khayal Tamer I |
| Role | Chief Commercial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 1083 |
| Date | 7 Jan |
| Name | Khayal Tamer I |
| Role | Chief Commercial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1083 |
| Date | 7 Jan |
| Name | Khayal Tamer I |
| Role | Chief Commercial Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 1083 |
| Date | 9 Dec |
| Name | Hernandez Gerardo |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 12463 |
| Date | 9 Dec |
| Name | Hernandez Gerardo |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 18922 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 7 Jan | Khayal Tamer I | Chief Commercial Officer | Acquired | M-Exempt | 1083 |
| 7 Jan | Khayal Tamer I | Chief Commercial Officer | Disposed | S-Sale | 1083 |
| 7 Jan | Khayal Tamer I | Chief Commercial Officer | Disposed | M-Exempt | 1083 |
| 9 Dec | Hernandez Gerardo | Chief Financial Officer | Acquired | A-Award | 12463 |
| 9 Dec | Hernandez Gerardo | Chief Financial Officer | Acquired | A-Award | 18922 |